Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Myriad Genetics submits premarket approval to FDA for BRACAnalysis


Monday, 7 Apr 2014 04:30pm EDT 

Myriad Genetics Inc:Says that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRAC Analysis testing as a companion diagnostic with olaparib.Olaparib is an investigational, orally active poly-ADP ribose polymerase (PARP) inhibitor being developed by AstraZeneca. 

Company Quote

36.18
0.17 +0.47%
29 Aug 2014